niacinamide and 2-chloro-n(6)-(3-iodobenzyl)adenosine-5'-n-methyluronamide

niacinamide has been researched along with 2-chloro-n(6)-(3-iodobenzyl)adenosine-5'-n-methyluronamide in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bar-Yehuda, S; Benjaminov, O; Ciuraru, NB; Cohen, S; Farbstein, M; Fishman, P; Fishman, S; Harpaz, Z; Kerns, WD; Medalia, G; Patoka, R; Silverman, MH; Singer, B; Stemmer, SM	1

Trials

1 trial(s) available for niacinamide and 2-chloro-n(6)-(3-iodobenzyl)adenosine-5'-n-methyluronamide

Article	Year
CF102 for the treatment of hepatocellular carcinoma: a phase I/II, open-label, dose-escalation study. The oncologist, 2013, Volume: 18, Issue:1 Topics: Adenosine; Adult; Aged; Apoptosis; Carcinoma, Hepatocellular; Child; Female; Humans; Leukocytes, Mononuclear; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Purinergic P1 Receptor Agonists; Receptor, Adenosine A3; Sorafenib; Wnt Signaling Pathway	2013

Article

Year

CF102 for the treatment of hepatocellular carcinoma: a phase I/II, open-label, dose-escalation study.

The oncologist, 2013, Volume: 18, Issue:1

Topics: Adenosine; Adult; Aged; Apoptosis; Carcinoma, Hepatocellular; Child; Female; Humans; Leukocytes, Mononuclear; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Purinergic P1 Receptor Agonists; Receptor, Adenosine A3; Sorafenib; Wnt Signaling Pathway

2013